Rhumbline Advisers lifted its stake in Boston Scientific Corporation (NYSE:BSX) by 2.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,370,126 shares of the medical equipment provider’s stock after acquiring an additional 56,189 shares during the period. Rhumbline Advisers owned 0.17% of Boston Scientific Corporation worth $69,137,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the company. Capital World Investors lifted its stake in shares of Boston Scientific Corporation by 1.6% in the 2nd quarter. Capital World Investors now owns 101,914,290 shares of the medical equipment provider’s stock worth $2,825,064,000 after acquiring an additional 1,611,442 shares during the period. BlackRock Inc. lifted its stake in shares of Boston Scientific Corporation by 4.6% in the 2nd quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after acquiring an additional 4,439,966 shares during the period. Vanguard Group Inc. lifted its stake in shares of Boston Scientific Corporation by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider’s stock worth $2,596,181,000 after acquiring an additional 2,522,556 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Boston Scientific Corporation by 22,491.6% in the 2nd quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after acquiring an additional 38,690,577 shares during the period. Finally, Winslow Capital Management LLC lifted its stake in shares of Boston Scientific Corporation by 21.9% in the 2nd quarter. Winslow Capital Management LLC now owns 11,212,783 shares of the medical equipment provider’s stock worth $310,818,000 after acquiring an additional 2,011,640 shares during the period. 90.50% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Boston Scientific Corporation (BSX) Shares Bought by Rhumbline Advisers” was published by Daily Political and is the property of of Daily Political. If you are accessing this article on another website, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/11/14/boston-scientific-corporation-bsx-shares-bought-by-rhumbline-advisers.html.

In other Boston Scientific Corporation news, SVP Maulik Nanavaty sold 57,031 shares of the company’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $27.28, for a total value of $1,555,805.68. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Timothy A. Pratt sold 10,104 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $27.46, for a total transaction of $277,455.84. Following the completion of the transaction, the executive vice president now owns 185,742 shares in the company, valued at approximately $5,100,475.32. The disclosure for this sale can be found here. In the last quarter, insiders sold 508,864 shares of company stock worth $14,581,669. Company insiders own 0.74% of the company’s stock.

Shares of Boston Scientific Corporation (NYSE BSX) traded up $0.09 during trading hours on Tuesday, hitting $28.45. 4,722,300 shares of the company traded hands, compared to its average volume of 6,640,035. The company has a current ratio of 0.72, a quick ratio of 0.50 and a debt-to-equity ratio of 0.58. The stock has a market cap of $38,943.84, a P/E ratio of 23.25, a PEG ratio of 2.19 and a beta of 1.00. Boston Scientific Corporation has a fifty-two week low of $19.67 and a fifty-two week high of $29.93.

Boston Scientific Corporation (NYSE:BSX) last released its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.31. The firm had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.21 billion. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.27 EPS. sell-side analysts predict that Boston Scientific Corporation will post 1.25 EPS for the current year.

A number of analysts have recently weighed in on BSX shares. Cowen and Company reaffirmed a “buy” rating and issued a $32.00 price target (up from $31.00) on shares of Boston Scientific Corporation in a research note on Friday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $32.00 price target on shares of Boston Scientific Corporation in a research note on Sunday, July 30th. UBS AG reaffirmed a “buy” rating and issued a $31.00 price target (up from $30.00) on shares of Boston Scientific Corporation in a research note on Tuesday, August 1st. Royal Bank Of Canada reissued a “buy” rating and set a $31.00 target price on shares of Boston Scientific Corporation in a research note on Friday, September 1st. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $34.00 target price on shares of Boston Scientific Corporation in a research note on Monday, October 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Boston Scientific Corporation currently has a consensus rating of “Buy” and an average target price of $30.77.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.